<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20049">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01923311</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-183-0160</org_study_id>
    <secondary_id>2013-001969-16</secondary_id>
    <nct_id>NCT01923311</nct_id>
  </id_info>
  <brief_title>Two Part Study to Study Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir (EVG) Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Subjects</brief_title>
  <official_title>A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG)Administered With a Background-Regimen (BR) Containing a Ritonavir-Boosted Protease Inhibitor (PI/r) in HIV-1 Infected, Antiretroviral Treatment-Experienced Pediatric Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, multicohort, two-part study to confirm the dose and
      evaluate the safety and tolerability of ritonavir-boosted elvitegravir (EVG/r) in HIV-1
      infected, treatment-experienced subjects aged 4 weeks to less than 18 years of age. The dose
      of EVG will be determined by intensive pharmacokinetic sampling at Day 10. The safety and
      antiviral activity of EVG will also be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Plasma pharmacokinetics (PK) parameters of EVG as measured by AUCtau and Cmax</measure>
    <time_frame>Day 10</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUCtau is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval)
Cmax is defined as the maximum concentration of drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events and laboratory abnormalities</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <safety_issue>No</safety_issue>
    <description>The incidence of treatment-emergent adverse events and laboratory abnormalities will be summarized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters of EVG as measured by Ctau, CL/F, and Vz/F</measure>
    <time_frame>Day 10</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ctau is defined as the observed drug concentration at the end of the dosing interval
CL/F is the apparent oral clearance following administration of the drug
Vz/F is the apparent volume of distribution of the drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with plasma HIV-1 RNA &lt; 50 and &lt; 400 copies/mL</measure>
    <time_frame>Weeks 24 and 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma log10 HIV-1 RNA</measure>
    <time_frame>Baseline to Weeks 24 and 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tanner Stages at Weeks 24 and 48, and age of first menses</measure>
    <time_frame>Weeks 24 and 48 and age of first menses</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tanner Stages at Weeks 24 and 48 will be summarized by baseline Tanner Stage using frequency and percentage. Age of first menses will be summarized descriptively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palatability of oral suspension formulation of EVG in appropriate age group</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to EVG</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <safety_issue>No</safety_issue>
    <description>Treatment adherence will be assessed at all post-baseline visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in CD4+ cell count (cells/Î¼L)</measure>
    <time_frame>Weeks 24 and 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in CD4 percentage</measure>
    <time_frame>Weeks 24 and 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Acquired Immune Deficiency Syndrome (AIDS)</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants age 12 to 17 will be enrolled.
Part A: No participants will be enrolled in Part A, as PK data is currently available for this age group.
Part B: Participants will receive Elvitegravir (EVG) plus a background regimen that includes a PI/r for up to 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants age 6 to 11 will be enrolled in Part A first. After pharmacokinetic (PK) assessment of Part A, participants will be enrolled in Part B.
Part A: Participants will receive Elvitegravir (EVG) plus a background regimen that includes a PI/r for 10 days. Participants with HIV-1 RNA &gt; 1,000 copies/mL who complete Part A may then choose to continue in Part B.
Part B: Following PK assessment, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elvitegravir</intervention_name>
    <description>EVG (50 mg, 85 mg, or 150 mg tablets or 5 mg/mL powder for oral suspension) administered orally once daily with food</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RTV-boosted PI</intervention_name>
    <description>Participants will receive a background regimen consisting of ritonavir (RTV; /r)-boosted protease inhibitor (PI/r). The PI/r contained in the background regimen must be one of the following: lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For subjects &lt; 2 months old, only lopinavir/r is allow. Use of additional antiretrovirals in background therapy may be allowed.
Participants with HIV-1 RNA &lt; 50 copies/mL will receive their current PI/r as background regimen
Participants with HIV-1 RNA &gt; 1,000 copies/mL will receive a newly constructed PI/r background regimen  selected by the investigator.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must meet all of the following inclusion criteria to be eligible for
        participation in this study. Subjects with screening results that do not meet eligibility
        criteria will not be allowed to rescreen.

          -  HIV-1 infected male and female subjects 4 weeks (gestational age of at least 44
             weeks) to less than 18 years of age at Baseline.

          -  Subjects are able to provide written assent if they have the ability to read and
             write.

          -  Parent or legal guardian able to provide written informed consent prior to any
             screening evaluations and willing to comply with study requirements.

          -  Body weight at screening greater than 5kg, 10.6kg, or 15kg dependent upon age cohort

          -  Adequate renal function

          -  Adequate hematologic function

          -  Hepatic transaminases (AST and ALT) less than or equal to 5 x upper     limit of
             normal (ULN)

          -  Total bilirubin less than or equal to 1.5 mg/dL, or normal direct bilirubin

          -  Negative serum pregnancy test

          -  Subjects with evidence of suppressed viremia

          -  Subjects failing a current antiretroviral regimen at study entry

          -  Male and female subjects of childbearing potential must agree to utilize highly
             effective contraception methods while on study treatment or agree to abstain from
             heterosexual intercourse throughout the study period and for 30 days following the
             last dose of study drug

          -  Must be willing and able to comply with all study requirements.

        Exclusion Criteria:

        Subjects who meet any of the following exclusion criteria are not to be enrolled in this
        study.

          -  Subjects with CD4+ cell counts at Screening of less than 50, 75, or 200 cells/mm3
             dependent on age cohort

          -  An AIDS defining condition with onset within 30 days prior to screening

          -  Life expectancy of less than 1 year

          -  For subjects with HIV-1 RNA greater than 1,000 copies/mL at screening, prior
             treatment of any duration with an integrase strand transfer inhibitor.

          -  An ongoing serious infection requiring systemic antibiotic therapy at the time of
             screening.

          -  Evidence of active pulmonary or extra-pulmonary tuberculosis disease

          -  Anticipated requirement for rifamycin treatment while participating in the study.

          -  Have any serious or active medical or psychiatric illness which, in the opinion of
             the Investigator, would interfere with subject treatment, assessment, or compliance
             with the protocol.

          -  Subjects experiencing decompensated cirrhosis

          -  A history of or ongoing malignancy other than cutaneous Kaposi's sarcoma (KS), basal
             cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma.

          -  Pregnant or lactating subjects.

          -  Current alcohol or substance abuse judged by the Investigator to potentially
             interfere with subject compliance.

          -  Have history of significant drug sensitivity or drug allergy.

          -  Known hypersensitivity to the study drug, the metabolites, or formulation excipients.

          -  Have previously participated in an investigational trial involving administration of
             any investigational agent within 30 days prior to the study dosing.

          -  Participation in any other clinical trial without prior approval from sponsor is
             prohibited while participating in this trial.

          -  Subjects receiving ongoing therapy with any medication that is not to be taken with
             EVG or a component of the BR, including drugs not to be used with ritonavir
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Bennett, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Skanda Goudar</last_name>
    <phone>650-522-4274</phone>
    <email>skanda.goudar@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marilyn Crain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jeffrey Goodman Clinic Los Angeles Gay and Lesbian Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Church Joseph, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elizabeth McFarland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida, Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mobeen H. Rathore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida College of Medicine</name>
      <address>
        <city>Tampla</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jorge Lujan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory-Children's Center - Ponce Family and Youth Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rana Chakraborty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ellen Cooper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine Pediatrics</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016-6481</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William Borkowsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Leonard Weiner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Coleen Cunningham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aditya Gaur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gloria Heresi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite-Universitaetsmedizin Berlin-Klinik fÃ¼r PÃ¤diatrie mit Schwerpunkt Pneumologie und Immunologie</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cornelia Feiterna-Sperling</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johann Wolfgang Goethe-University Hospital</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christoph Koenigs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOSD Pediatria ad Alta IntensitÃ  di Cura</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Susanna Esposito</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Pavia - Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lorenzo Minoli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Be Part Yoluntu Centre</name>
      <address>
        <city>Cape Town</city>
        <zip>7646</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lize Hellstrom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mpati Medical Centre</name>
      <address>
        <city>Dundee</city>
        <zip>3000</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jan Fourie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gulam Latiff Private Practice</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gulam Latiff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rahima Moosa Mother and Child Hopsital</name>
      <address>
        <city>Johannesburg</city>
        <zip>2112</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Renate Strehlau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit</name>
      <address>
        <city>Soweto</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Avy Violari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan De Deu</name>
      <address>
        <city>Barcelona</city>
        <zip>8950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claudia Fortuny Guasch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario De Getafe</name>
      <address>
        <city>Getafe Madrid</city>
        <zip>28095</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>JosÃ© TomÃ¡s Ramos Amador</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria Isabel Gonzalez-Tome</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thai Red Cross AIDS Research Centre (HIV-NAT)</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wasana Prasitsuebsai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kulkanya Chokephaibulkit</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pope Kosalaraksa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joint Clinical Research Centre</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Victor Musiime</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>Uganda</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>August 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatrics</keyword>
  <keyword>Adolescents</keyword>
  <keyword>HIV</keyword>
  <keyword>HIV-1</keyword>
  <keyword>Treatment-experienced</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
